No association between perfluoroalkyl chemicals and hypertension in children by Geiger, Sarah Dee et al.
© 2014 Geiger et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Integrated Blood Pressure Control 2014:7 1–7
Integrated Blood Pressure Control Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1
O r I g I n a l  r e s e a r C h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/IBPC.S47660
No association between perfluoroalkyl chemicals 




1Department of Public Health, 
Northern Illinois University,  
School of Nursing and Health  
Studies, DeKalb, IL, 2registration 
and Records, North Carolina State 
University, Raleigh, NC, 3Department 
of Epidemiology, School of Public 
Health, West Virginia University, 
Morgantown, WV, USA
Correspondence: Sarah D Geiger 
Department of Public Health, Northern 
Illinois University  
255 Wirtz Hall, DeKalb, IL 60115, USA 
Tel +1 815 753 5590 
Fax +1 815 753 5406 
email geiger@niu.edu
Background: Hypertension is a leading cause of cardiovascular disease worldwide. 
Perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) are perfluoroalkyl 
chemicals (PFCs) used in the manufacture of common consumer products and detected in the 
blood of the majority of Americans. Emerging biological data suggest that PFC exposure may 
have a role in the development of hypertension. However, the association between PFCs and 
hypertension has not yet been explored in humans. Therefore, we examined this association in 
a representative sample of US children.
Methods: A cross-sectional study was performed on 1,655 children from the National Health 
and Nutrition Examination Survey, 1999–2000 and 2003–2008. The main outcome of interest 
was hypertension, defined as age, height, and sex specific systolic and/or diastolic blood pres-
sure level at the 95th percentile.
Results: We found no association between serum levels of PFOA and PFOS and hypertension 
in either unadjusted or multivariable-adjusted analyses controlling for age, sex, race-ethnicity, 
body mass index, annual household income, moderate activity, total serum cholesterol, and 
serum cotinine. Compared with the lowest quartile, the multivariable-adjusted odds ratio (95% 
confidence interval) of hypertension in the highest quartile of exposure was 0.69 (0.41–1.17) 
for PFOA and 0.77 (0.37–1.61) for PFOS (all P-trend values .0.30).
Conclusion: Our findings indicate that exposure to PFOA or PFOS is not significantly asso-
ciated with hypertension in children at the lower PFC exposure levels typical of the general 
population.
Keywords: perfluorooctanoic acid, perfluorooctane sulfonate, perfluoroalkyl chemicals, blood 
pressure, children
Introduction
Perfluoroalkyl chemicals (PFCs) are detectable in the blood of more than 98% of the 
US population.1 They persist in the environment, bioaccumulate, biomagnify along 
food chains, and have been shown to cause developmental, endocrine, and other adverse 
health outcomes in laboratory animals.2,3 PFCs are found in surfactants, lubricants, 
polishes, paper and textile coatings, food packaging, and fire-retarding foams, among 
many other consumer products. Perfluorooctanoic acid (PFOA) and perfluorooctane 
sulfonate (PFOS) are two of the most studied PFCs.
Hypertension is present in 29.0% of the adult US population and 3.2% of 
adolescents aged 11–17 years.4 It is also the leading cause of cardiovascular disease 
worldwide.5 Hypertension accounted for 56.5% of all-cause mortality in 2006, and 
death rates from hypertension increased by 19.5% from 1996 to 2006.6 While traditional 





factors such as weight gain,7,8 smoking,9 and lack of physical 
activity10 have been shown to be positively associated with 
hypertension, emerging literature suggests a role for common 
environmental exposures, including other manmade organic 
compounds,11–15 in the development of hypertension.
A positive association between exposure to PFCs and 
hypertension is plausible. In a 2012 study, PFOA was reported 
to be linked to pregnancy-induced hypertension; this repre-
sents the only known epidemiologic study examining the 
association between PFOA and any form of high blood pres-
sure.16 However, PFCs such as PFOA and PFOS have been 
linked to higher cholesterol levels,17 hyperuricemia,18,19 meta-
bolic syndrome,20 insulin resistance,20 and high serum 
gamma-glutamyl transpeptidase in previous epidemiologic 
studies,21–24 all of which are factors reported to be indepen-
dently related to hypertension.18,25–28 In vitro studies have 
shown PFC exposure to be associated with oxidative stress29,30 
and endothelial dysfunction.31,32 To our knowledge, the asso-
ciation between PFCs and hypertension has not been explored 
in children. Therefore, we sought to examine the association 
between PFCs and blood pressure levels in children using 
data from the nationally representative National Health and 
Nutrition Examination Survey (NHANES).
Materials and methods
Study population
This study uses 8 years of merged data from the NHANES, 
years 1999–2000, 2003–2004, 2005–2006, and 2007–2008. 
PFC data were not available for years 2001–2002. Data col-
lection methods for NHANES have been published and are 
available online.33 NHANES included a stratified multistage 
probability sample, representative of the noninstitutionalized 
civilian US population. Selection was based on counties, cen-
sus blocks, households, and individuals within households, 
and included the oversampling of non-Hispanic Blacks and 
Mexican Americans in order to provide stable estimates of 
these groups. Subjects were required to sign a consent form 
before their participation, and approval was obtained from the 
Human Subjects Committee in the US Department of Health 
and Human Service. The survey also includes biomonitoring 
for select environmental chemicals, including PFCs, in a 
random one third subsample of participants by the National 
Center for Environmental Health.
The central variables for this analysis are laboratory mea-
surements of PFOA, PFOS, and blood pressure, and the study 
sample consisted of children 18 years of age and younger who 
took part in both the interview and examination components. 
Because PFC levels are not sampled for children under the 
age of 12 years, the age range for this study was children 
12–18 years (n=1,788). We additionally excluded those with 
missing values for covariates used in the multivariable model, 
including age, sex, race-ethnicity, annual household income, 
physical activity, total serum cholesterol, and serum cotinine 
(n=133). The final sample size of children included in this 
analysis was n=1,655.
Main outcome of interest: blood pressure
The main outcome of interest was systolic and diastolic 
blood pressure and the presence of hypertension. Blood 
pressure was measured in the examination component 
of the survey. The mean of up to three blood pressure 
readings was used for both systolic and diastolic blood 
pressure. Seated blood pressure was taken by a physician 
using a mercury sphygmomanometer following 5 minutes 
of rest according to American Heart Association and JNC7 
(Seventh Report of the Joint National Committee on Pre-
vention, Detection, Evaluation, and Treatment of High 
Blood Pressure) guidelines.34,35 Details of blood pressure 
measurement and quality control procedures are available 
online.36 Subjects were considered hypertensive if they had 
an average blood pressure level at the 95th percentile or 
greater, adjusted for age, height, and sex, as recommended 
by the National High Blood Pressure Education Program 
Working Group on Hypertension Control in Children and 
Adolescents.37,38
exposure measurements
Sex, age, race/ethnicity, education level, physical activity, 
and annual household income were assessed by a standard-
ized interview. Body mass index was calculated using the 
formula weight (kg)/height (m2). Moderate physical activity 
was defined as participation in any moderate recreational 
physical activity. NHANES participants also provided blood 
samples for various laboratory measurements. Details of 
blood collection and analysis are provided in the NHANES 
Laboratory/Medical Technologists Procedures Manual.39 
Briefly, serum total cholesterol was measured enzymati-
cally. Perfluoroalkyl chemicals were measured in serum 
by the National Center for Environmental Health using 
automated solid-phase extraction coupled with isotope 
dilution high-performance liquid chromatography-tandem 
mass spectrometry. Our study focused on PFOA and PFOS, 
two specific PFCs. Both were detected in the serum of over 
98% of participants; values below the limit of detection were 
reported by NHANES as the limit of detection divided by 
the square root of 2.39




PFCs and blood pressure in children
Statistical analysis
Serum PFOA and PFOS were analyzed as continuous and 
categorical variables. For analysis as a continuous vari-
able, PFC values were log-transformed (base e) to correct 
skewed distributions. For analysis as a categorical variable, 
we categorized PFOA and PFOS into quartiles of increasing 
exposure. Linear regression models were used to examine 
mean change in blood pressure with increasing category of 
PFC, using the lowest PFC quartile as the referent. We ran 
two nested models: unadjusted and multivariable-adjusted, 
controlling for age (,18 years), sex (male, female), race-
ethnicity (non-Hispanic White, non-Hispanic Black, Mexican 
American, other), body mass index (underweight, healthy 
weight, overweight, obese), annual household income 
categories (,$4,999, $5,000–$9,999, $10,000–$14,999, 
$15,000–$19,999, $20,000–$24,999, $25,000–$34,999, 
$35,000–$44,999, $45,000–$54,999, $55,000–$64,999, 
$65,000–$74,999, .$75,000), moderate activity (absent, 
present), and serum total cholesterol (mg/dL). We also ran 
unadjusted and multivariable-adjusted logistic regression 
models to calculate the odds ratio (95% confidence interval) 
of hypertension for each PFC quartile, using quartile 1 as 
the referent. Trends in the odds ratio of hypertension across 
increasing serum PFC quartiles were determined by model-
ing the PFCs as ordinal variables. In a series of supplemental 
analyses, we explored the possibility of a nonlinear relation-
ship between PFOA, PFOS, and blood pressure levels. We 
conducted nonlinear regression modeling using the NLIN 
procedure.40,41
Sample weights that account for unequal probabilities of 
selection, oversampling, and nonresponse in the NHANES 
survey were applied for all analyses, as recommended by 
the National Center for Health Statistics.42 Analyses were 
conducted using SAS (version 9.2, SAS Institute Inc., Cary, 
NC, USA) software. Standard errors were estimated using 
the Taylor series linearization method.
Results
Characteristics of the study population (n=1,655) are shown 
in Table 1. Nearly half of the study population was female and 
the mean age of 15.1 years had a standard error of only ±0.1. 
The majority of the sample was non-Hispanic White, but 
Blacks (14.3%) and Mexican Americans (11.8%) were rep-
resented as well. Nearly half of study participants fell into 
the highest household income category and almost 37.0% of 
the children were overweight or obese.
Our first multivariate analysis consisted of linear regres-
sion modeling to study the association between increasing 
quartiles of serum PFOA and PFOS and the mean change 
in serum systolic (Table 2) and diastolic (Table 3) blood 
pressure level in mmHg. The association between PFCs and 
blood pressure was not significant in either model (all P-trend 
values .0.30). The relationship was also not significant in 
either model for log-transformed PFOA or PFOS.
In addition, we also analyzed the putative association 
between increasing quartiles of serum PFOA and PFOS 
and the presence of hypertension using logistic regression 
models (Table 4). Results were similar to those of the linear 
regression analysis in that we did not observe an association 
between PFOA or PFOS and hypertension in any model (all 
P-trend values .0.30). The relationship was also not signifi-
cant in either model for log-transformed PFOA or PFOS.
Nonlinear regression analyses were consistent with 
linear and logistic regression modeling. No association 
was observed between PFOA or PFOS and blood pressure 
levels.
Discussion
We did not f ind a positive association between expo-
sure to PFOA and PFOS and elevated blood pressure 
levels in a nationally representative sample of children. 
Table 1 Characteristics of study population
Characteristics Percentage or mean 
value ± standard error




 Non-Hispanic white 62.5
 Non-Hispanic Black 14.3
 Mexican american 11.8
 Other 11.4
Annual household income
 Under $25,000 23.9
 $25,000–$54,999 28.1
 $55,000 and over 48.1
No moderate activity, % 17.9
Body mass index category, %
 Underweight 4.1
 Normal weight 59.2
 Overweight 18.2
 Obese 18.5
 Total cholesterol, mg/dL 159.7±1.1
 Serum cotinine, ng/mL 15.0±1.7
 Systolic blood pressure, mmHg 110.0±0.5
 Diastolic blood pressure, mmHg 60.5±0.4
 Hypertension, % 23.4
 PFOA, ng/mL 4.4±0.1
 PFOS, ng/mL 18.4±0.5
Abbreviations: PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate.





Multivariable models controlled for age, sex, race-ethnicity, 
body mass index, annual household income, physical activ-
ity, serum total cholesterol levels, and serum cotinine levels. 
Our analysis contributes to the extant literature by being the 
first to examine the association between PFC exposure and 
hypertension in humans.
Hypertension is a common condition which is also a 
strong, independent risk factor for cardiovascular disease.5 
The pathophysiology of hypertension is incompletely 
understood, but several factors have been implicated, includ-
ing psychosocial stress, excessive sodium-retaining hormone 
production, increased sympathetic nervous system activity, 
and vasodilator deficiency.43 Hypertension remains a major 
public health problem despite substantial advances in our 
understanding of its etiology, pathophysiology, and effective 
treatment.44
No previous study has examined the association between 
PFCs and hypertension. In relation to our hypothesis, one 
Table 2 Association between serum PFOA, PFOS levels, and systolic blood pressure
Plasma PFC level Sample  
size (n)
Unadjusted mean change in blood  
pressure in mmHg (95% CI)
Multivariable-adjusted mean change  
in blood pressure in mmHg (95% CI)‡
PFOa*
 Quartile 1 398 0 (referent) 0 (referent)
 Quartile 2 433 2.51 (0.17, 4.85) 0.60 (-1.39, 2.60)
 Quartile 3 410 1.63 (-0.99, 4.25) 0.21 (-2.14, 2.57)
 Quartile 4 414 1.43 (-1.14, 4.00) -0.89 (-3.06, 1.28)
 P-trend 0.4808 0.3550
 Log-transformed PFOA 0.01 (-1.70, 1.71) -1.22 (-2.74, 0.31)
PFOs†
 Quartile 1 413 0 (referent) 0 (referent)
 Quartile 2 413 0.84 (-1.13, 2.80) -0.25 (-1.87, 1.36)
 Quartile 3 413 0.70 (-1.64, 3.04) 0.29 (-1.76, 2.34)
 Quartile 4 416 0.66 (-1.80, 3.12) -0.11 (-2.07, 1.85)
 P-trend 0.6230 0.9210
 Log-transformed PFOS 0.26 (-1.16, 1.69) -0.04 (-1.19, 1.12)
Notes: *Plasma PFOa quartiles: quartile 1 (,2.9 ppb), quartile 2 (2.9–4.0 ppb), quartile 3 (4.1–5.4 ppb), quartile 4 (.5.4 ppb); †plasma PFOs quartiles: quartile 1 (,10.8 ppb), 
quartile 2 (10.8–16.6 ppb), quartile 3 (16.7–25.5 ppb), quartile 4 (.25.5 ppb); ‡adjusted for age (years), sex (men, women), race-ethnicity (non-Hispanic White, non-Hispanic 
Black, Mexican American, other), body mass index categories (underweight, healthy weight, overweight, obese), annual household income categories, moderate activity 
(absent, present), total cholesterol (mg/dL) and serum cotinine (ng/mL).
Abbreviations: CI, confidence interval; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate; PFC, perfluoroalkyl chemicals; ppb, parts per billion.
Table 3 Association between serum PFOA, PFOS levels, and diastolic blood pressure
Plasma PFC level Sample  
size
Unadjusted mean change in blood 
pressure in mmHg (95% CI)
Multivariable-adjusted mean change  
in blood pressure in mmHg (95% CI)‡
PFOa*
 Quartile 1 398 0 (referent) 0 (referent)
 Quartile 2 433 -0.27 (-2.27, 1.73) -0.06 (-2.11, 1.99)
 Quartile 3 410 1.10 (-0.72, 2.93) 1.25 (-0.53, 3.03)
 Quartile 4 414 0.32 (-1.64, 2.28) 0.33 (-1.71, 2.37)
 P-trend 0.4156 0.4205
 Log-transformed PFOA 0.25 (-1.11, 1.61) 0.36 (-0.99, 1.71)
PFOs†
 Quartile 1 413 0 (referent) 0 (referent)
 Quartile 2 413 0.38 (-1.73, 2.48) 0.42 (-1.61, 2.45)
 Quartile 3 413 1.39 (-0.86, 3.64) 0.99 (-1.20, 3.17)
 Quartile 4 416 0.51 (-1.41, 2.43) 0.17 (-1.95, 2.29)
 P-trend 0.4310 0.7503
 Log-transformed PFOS 0.83 (-0.36, 2.02) 0.47 (-0.81, 1.74)
Notes: *Plasma PFOa quartiles: quartile 1 (,2.9 ppb), quartile 2 (2.9–4.0 ppb), quartile 3 (4.1–5.4 ppb), quartile 4 (.5.4 ppb); †plasma PFOs quartiles: quartile 1 (,10.8 
ppb), quartile 2 (10.8–16.6 ppb), quartile 3 (16.7–25.5 ppb), quartile 4 (.25.5 ppb); ‡adjusted for age (years), sex (men, women), race-ethnicity (non-Hispanic White, non-
Hispanic Black, Mexican American, other), body mass index categories (underweight, healthy weight, overweight, obese), annual household income categories, moderate 
activity (absent, present), total cholesterol (mg/dL), and serum cotinine (ng/mL).
Abbreviations: CI, confidence interval; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate; PFC, perfluoroalkyl chemicals; ppb, parts per billion.




PFCs and blood pressure in children
recent study analyzed the relationship between PFCs and 
pregnancy-induced hypertension, a condition of high blood 
pressure seen in pregnancy that can lead to potentially severe 
health risks to the mother as well as to the fetus.16 This study 
was conducted by a team of scientists who were appointed 
by the court to study the health effects of PFC exposure 
following litigations between DuPont Chemical Works and 
more than 69,000 plaintiffs exposed to high levels of PFOA 
in drinking water due to a chemical leak from this plant. 
This panel of scientists has recently publicly announced 
several findings, including a positive association between 
PFOA and pregnancy-induced hypertension; however, 
these findings have not yet been subjected to scientific peer 
review. In addition, there is indirect evidence supporting our 
hypothesis of a putative association between PFC exposure 
and hypertension.
Several factors that are known to be associated with 
increased risk of hypertension,25–27 including elevated cho-
lesterol,28 hyperuricemia,19 oxidative stress,29,30 endothelial 
dysfunction,31 insulin resistance,20 weight gain,45 and elevated 
serum gamma-glutamyl transpeptidase,29 have been shown 
to be independently related to PFC exposure. Low-level 
exposure to PFCs has also been shown to be significantly 
associated with other health outcomes such as dyslipidemia,24 
hyperuricemia,46 thyroid disease,47 and changes in liver 
enzymes,20 and therefore may be deleterious to public health 
even in the absence of an association with hypertension. 
Finally, high-level PFC exposure is known to be linked to a 
host of negative health outcomes, including dyslipidemia,17 
hyperuricemia,19 early menopause,48 and osteoarthritis,49 
among others. Despite these leads, our study did not find an 
association between PFC exposure and the presence of hyper-
tension in a multiethnic, representative sample of children.
In a recent population-based study, Seals et al50 
demonstrated that PFOA has a concentration-dependent 
half-life of 2.9 years at higher serum levels and 8.5 years 
at lower levels, suggesting that at lower serum levels 
PFCs persist in the body for a longer period of time. 
Given that PFCs are present in the blood of the majority 
of Americans only at low levels,3 the current study of the 
relationship between PFC exposure and hypertension in 
the representative NHANES sample renders our results to 
be more generalizable and relevant than studies from high 
PFC exposure groups, such as the study linking PFCs to 
pregnancy-induced hypertension.16 Also, children are an 
ideal sample in which to study environmental cardiovascular 
risk factors because there is now an emerging consensus that 
the development of cardiovascular disease in adulthood is 
preceded by metabolic changes occurring in childhood,51–53 
and compared with adults, children tend to have limited 
cumulative exposure to lifestyle/behavioral risk factors for 
chronic diseases such as smoking and alcohol intake, and 
therefore the potential for confounding by these factors 
tends to be limited.
Other strengths of our study include its relatively large 
sample size, availability of detailed data on confounders, 
and standardized, high-quality data collection. The primary 
limitation is the cross-sectional nature of the study, which 
Table 4 Association between plasma PFOA, PFOS levels, and hypertension




Unadjusted odds  
ratio (95% CI)
Multivariable-adjusted 
odds ratio (95% CI)‡
PFOa*
 Quartile 1 398 20.4 1 (referent) 1 (referent)
 Quartile 2 433 24.7 1.28 (0.77, 2.15) 0.89 (0.53, 1.49)
 Quartile 3 410 24.8 1.29 (0.70, 2.38) 0.96 (0.53, 1.73)
 Quartile 4 414 23.0 1.17 (0.66, 2.07) 0.69 (0.41, 1.17)
 P-trend 0.6522 0.2477
 Log-transformed PFOA 1.03 (0.70, 1.52) 0.76 (0.53, 1.10)
PFOs†
 Quartile 1 413 22.6 1 (referent) 1 (referent)
 Quartile 2 413 26.9 1.26 (0.75, 2.11) 0.99 (0.55, 1.78)
 Quartile 3 413 20.3 0.88 (0.47, 1.63) 0.73 (0.36, 1.48)
 Quartile 4 416 22.9 1.02 (0.52, 1.99) 0.77 (0.37, 1.61)
 P-trend 0.7527 0.3625
 Log-transformed PFOS 0.96 (0.70, 1.32) 0.83 (0.58, 1.19)
Notes: *Plasma PFOa quartiles: quartile 1 (,2.9 ppb), quartile 2 (2.9–4.0 ppb), quartile 3 (4.1–5.4 ppb), quartile 4 (.5.4 ppb); †plasma PFOs quartiles: quartile 1 (,10.8 
ppb), quartile 2 (10.8–16.6 ppb), quartile 3 (16.7–25.5 ppb), quartile 4 (.25.5 ppb); ‡adjusted for age (years), sex (men, women), race-ethnicity (non-Hispanic White, non-
Hispanic Black, Mexican American, other), body mass index categories (underweight, healthy weight, overweight, obese), annual household income categories, moderate 
activity (absent, present), total cholesterol (mg/dL) and serum cotinine (ng/mL).
Abbreviations: CI, confidence interval; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate; PFC, perfluoroalkyl chemicals; ppb, parts per billion.





prohibits drawing conclusions about the temporal nature of 
the PFC-blood pressure association.
In summary, we found no association between serum PFC 
levels and blood pressure in a representative, multiethnic sample 
of US children. Results were consistent across regression mod-
els in separate analyses for PFOA and PFOS. Future research 
should be conducted to confirm or disprove our results.
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